-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Ranked Among the Top 200 Manufacturing Enterprises in the Beijing-Tianjin-Hebei Region
Category:
发布时间：2024-09-25
【概要描述】
Recently, the Federation of Enterprises and the Entrepreneurs Association of Beijing Municipality, Tianjin Municipality, and Hebei Province jointly released the 2024 Top 200 Enterprises in the Beijing–Tianjin–Hebei Region. Shijiazhuang Sihua Pharmaceutical Group was included in the list of the top 200 manufacturing enterprises in the region, ranking 106th.
Recently, the Federation of Enterprises and the Entrepreneurs Association of Beijing, Tianjin, and Hebei Province jointly released the 2024 Top 200 Enterprises in the Beijing–Tianjin–Hebei Region, with Shijiazhuang Sihua Pharmaceutical Group ranking 106th among the top 200 manufacturing enterprises in the region.
In recent years, the Group has thoroughly implemented the new development philosophy, taking it as its mission to research, develop, and produce more “Chinese medicines” that are tailored to the genetic heritage and physical characteristics of the Chinese population. Centering on the paramount task of high-quality development, the Group has firmly seized the favorable opportunities and supportive policy environment created by the state’s encouragement of the pharmaceutical industry, kept a keen eye on the cutting edge of industry development, and rigorously pursued an innovation-driven strategy. With a relentless, forward-looking approach, the Group has leveraged project construction to continuously promote the integrated development of the innovation chain, talent chain, industrial chain, and supply chain, thereby fostering and expanding new drivers of productivity. By harnessing technological innovation and digital transformation, the Group has empowered the seamless translation of integrated “active pharmaceutical ingredient + formulation” innovations into marketable products and facilitated industrial upgrading. As a result, the foundation for the company’s high-quality development has grown ever stronger, while its innovative influence and market competitiveness have consistently reached new heights.
According to reports, the 2024 Ranking of the Top 200 Enterprises in the Beijing–Tianjin–Hebei Region is guided by the All-China Federation of Industry and Commerce and the China Enterprise Confederation, and jointly organized by the Tianjin Enterprise Federation and the Tianjin Entrepreneurs Association, the Beijing Enterprise Federation and the Beijing Entrepreneurs Association, and the Hebei Provincial Enterprise Federation and the Hebei Provincial Entrepreneurs Association. Following established domestic and international practices, the ranking uses 2023 corporate revenue as the criterion for inclusion, and jointly releases the 2024 list of the Top 200 Enterprises in the Beijing–Tianjin–Hebei Region, which comprises the Top 200 Enterprises in the region, the Top 200 Manufacturing Enterprises in the region, and the Top 200 Service Enterprises in the region. The purpose of this selection process is to encourage enterprises across the Beijing–Tianjin–Hebei area, particularly large ones, to proactively pursue high-quality development, continuously deepen reform, refine and improve institutional mechanisms that are well-suited to market-oriented and globalized competition, strengthen R&D and innovation capacity, align innovation chains closely with industrial value chains, accelerate technological innovation and industrial upgrading, and strive to make new contributions and assume greater responsibilities in advancing coordinated development among Beijing, Tianjin, and Hebei.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091